MIB-1 in relation to tumour response and survival in patients with breast cancer treated with primary systemic therapy

Breast

Volumn 8, Issue 2, 1999, Pages 77-83

  Levack, P A ^a,d   Forrest, A P M ^c   Miller, E P ^b   Cameron, D A ^b   Anderson, E D ^c   Leonard, R C F ^a   Chetty, U ^c   McIntyre, M ^b   Miller, W R ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c University Department of Surgery   (United Kingdom)

^d NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FORMESTANE; HORMONE; PREDNISOLONE; TAMOXIFEN; TUMOR MARKER; VINCRISTINE;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CORRELATION FUNCTION; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TUMOR;

EID: 0032789116     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(99)90004-8     Document Type: Article

References (42)

1. Anderson E D C, Forrest A P M, Hawkins R A, Anderson T J, Leonard R C R, Chetty U. Primary systemic therapy for operable breast cancer. Br J Cancer 1991; 63: 561-566.
2. Mauriac L, Durand M, Avril A, Dilhuydy J-M. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumours larger than 3 cm. Annals of Oncol 1991; 2: 347-354.
3. Scholl S M, Fourquet A, Asselain B et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast onserving surgery: preliminary results of a randomised trial: S6. European J Cancer 1994; 30A(5): 645-652.
4. Cameron D A, Anderson E D C, Levack P, et al. Primary sytemic therapy for operable breast cancer - survival data following chemotherapy and hormone therapy. Br J Cancer 1997; 76: 1099-1105.
5. Hawkins R A, Sangster K, Levack P A et al. The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer; correlation with biochemical assay and prediction of response to endocrine therapy. Br J Cancer 1988; 58: 77-80.
6. Millis R R, Rubens R D, Masters J R W, Minton M J. Histological grade and response to endocrine therapy in breast cancer. Lancet 1981; ii: 101.
7. Silvestrini R. Biological predictors of response to hormone and chemotherapy. The Breast 1996; 5: 163.
8. Henry J A, Piggott N H, Mallick U K et al. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 1991; 63: 615-622.
9. Thompson A M, Hawkins R A, Elton R A, Steel C M, Chetty U, Carter D C. pS2 is an independent factor of good prognosis in primary breast cancer. Br J Cancer 1993; 68(1): 93-96.
10. Ravdin P M, Grees S, Dorr T M, et al. Prognostic significance of progesterone receptor levels in oestrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen; results of a prospective southwest oncology Group study. J Clin Oncol 1992; 10(8): 1284-1291.
11. Keen J C, Miller E P, Bellamy C, Dixon J M, Miller W R. P-glycoprotein and resistance to tamoxifen. Lancet 1994; 343: 1047-1048.
12. Spyratos F, Andrieu C, Hacene K, Chambon P, Rio M C. pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 1994; 69: 394-397.
13. Nicholson R I, Bouzubar, Walker K J et al. Hormone sensitivity in breast cancer. Eur J Cancer 1991; 27(7): 908-913.
14. Nicholson R L, MCLelland R A, Finlay P, et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993; 29A(7): 1018-1023.
15. O'Reilly S, Camplejohn R S, Rubens R D, Richards M A. DNA flow cytometry and response to pre-operative chemotherapy for primary breast cancer. Eur J Cancer 1992; 28: 681-683.
16. Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H, Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 1989; 81: 1383-1387.
17. Remvikos Y. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 1993; 29A: 1843-1848.
18. O'Reilly S M, Camplejohn R S, Millis R R, Rubens R D, Richards M A. Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer 1990; 26: 1035-1038.
19. Stal O, Rutqvist L E, Carstensen J M, et al. S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br J Cancer 1994; 70: 1258-1262.
20. Cattorett G, Becker M H G, Key G, et al. Monoclonal antibodies against recombitant parts of the K1-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin fixed paraffin sections. J Pathol 1992; 168: 357-363.
21. Shi S R, Key M E, Kaira K L. Antigen retrieval in formalin fixed, paraffin embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39: 741.
22. Forrest A P M, Levack P A, Chetty U, et al. A human tumour model. Lancet 1986; ii: 840-842.
23. Hsu S M, Raine L, Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-580.
24. Cattoretti G, Berti E, Schiro R, D'Amato L, Valeggio C, Rilke F. Improved avidin biotin peroxidase complex (ABC) staining. Histochem J 1988; 120: 75-80.
25. Weidner N, Moore D H, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumour grade in breast carcinomas using the novel 'paraffin' reactive MIB1 antibody. Hum Pathol 1994; 2: 337-342.
26. Hawkins R A, Black R, Steele R J C, Dixon J M J, Forrest A P M. Oestrogen receptor concentration in primary breast cancer and axillary node metastases. Breast Cancer Res Treat 1981; 1: 245-251.
27. Bouzubar N, Walker K J, Griffiths K, Ellis I O, Elston C W, Robertson I F R, et al. Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 1989; 943-947.
28. Veronese S M, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P. Proliferation index as a prognostic marker in breast cancer. Cancer 1993; 71(12): 3926-3931.
29. Pinder S E, Wencyk P, Sibberring D M, Bell J A, Elston C W, Nicholson R, et al. Assessment of the new proliferative marker MIB 1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995; 71: 146-149.
30. Querzoli P, Albonico G, Ferretti S, Magri E, Indelle M, Nenci I. MIB-1 proliferative activity in invasive breast cancer measured by image analysis. J Clin Path 1996; 49: 926-930.
31. Keshgegian A A, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, K1-67 and MIB-1. Am J Clin Path 1995; 104: 42-49.
32. Ellis P A, Makris A, Burton S A, et al. Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas. Br J Cancer 1996; 73(5): 640-643.
33. Bottini A, Berruti A, Bersiga A, et al. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Research 1996; 16(5B): 3105-3110.
34. Bonetti A, Sperotto L, Turazza M et al. Tumour proliferative activity and response to first line chemotherapy in advanced breast cancer. Proc Ann Meet Am Soc Clin Oncol 1994; 13: A1-12.
35. Swenerton K D, Legha S S, Smith T, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979; 39(5): 1552-1562.
36. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumours with diameters of three cm. or more. 1. Natl Cancer Inst 1990; 82: 1539-1545.
37. Mullen P, Scott W N, Miller W R. Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br J Cancer 1991; 63: 930-932.
38. Sutherland R L, Hall R E, Taylor I W. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and the effects of tamoxifen on exponentially growing and plateau phase cells. Cancer Res 1983; 43: 3998-4006.
39. Danova M, Giordano M, Pellicciari C, et al. Cell cycle kinetic effects of tamoxifen on human breast cancer cells. Annals of the New York Academy of Sciences 1993; 698: 174-181.
40. Clarke R B, Laidlaw I J, Jones L J, Howell A, Anderson E. Effect of tamoxifen on Ki-67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 1993; 67(3): 606-611.
41. Spyratos F, Mayras C, Briffod M, et al. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cancer 1992; 69: 470-475.
42. Bottini A, Berruti A, Bersiga A, et al. Effect of neoadjuvant chemotherapy on Ki-67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Research 1996; 16(5B): 3105-3110.